Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 260

1.

Novel biomarkers of acute kidney toxicity.

Goodsaid FM, Blank M, Dieterle F, Harlow P, Hausner E, Sistare F, Thompson A, Vonderscher J.

Clin Pharmacol Ther. 2009 Nov;86(5):490-6. doi: 10.1038/clpt.2009.149.

PMID:
19710639
2.

Promises of biomarkers in drug development--a reality check.

Marrer E, Dieterle F.

Chem Biol Drug Des. 2007 Jun;69(6):381-94. Review.

PMID:
17581232
3.

Application of proteomic technologies in the drug development process.

Walgren JL, Thompson DC.

Toxicol Lett. 2004 Apr 1;149(1-3):377-85. Review.

PMID:
15093284
4.
5.

Quantitative proteomics for drug toxicity.

Gao Y, Holland RD, Yu LR.

Brief Funct Genomic Proteomic. 2009 Mar;8(2):158-66. doi: 10.1093/bfgp/elp006. Review.

PMID:
19351682
6.

Biomarkers in drug discovery and development: from target identification through drug marketing.

Colburn WA.

J Clin Pharmacol. 2003 Apr;43(4):329-41. Review.

PMID:
12723454
7.

Proteomics approach to illustrate drug action mechanisms.

Wang Y, Chiu JF, He QY.

Curr Drug Discov Technol. 2006 Sep;3(3):199-209. Review.

PMID:
17311565
8.

Application of proteomics for discovery of protein biomarkers.

Hale JE, Gelfanova V, Ludwig JR, Knierman MD.

Brief Funct Genomic Proteomic. 2003 Oct;2(3):185-93. Review.

PMID:
15239922
9.

Early drug safety evaluation: biomarkers, signatures, and fingerprints.

Roberts R, Cain K, Coyle B, Freathy C, Leonard JF, Gautier JC.

Drug Metab Rev. 2003 Nov;35(4):269-75. Review.

PMID:
14705860
10.

Molecular biomarkers in drug development.

Lewin DA, Weiner MP.

Drug Discov Today. 2004 Nov 15;9(22):976-83. Review.

PMID:
15539141
11.

Discovery and development of biomarkers of neurological disease.

Dunckley T, Coon KD, Stephan DA.

Drug Discov Today. 2005 Mar 1;10(5):326-34. Review.

PMID:
15749281
12.

Genomic-based biomarkers of drug-induced nephrotoxicity.

Davis JW, Kramer JA.

Expert Opin Drug Metab Toxicol. 2006 Feb;2(1):95-101. Review.

PMID:
16863471
13.

Emerging applications of kinetic biomarkers in preclinical and clinical drug development.

Turner SM, Hellerstein MK.

Curr Opin Drug Discov Devel. 2005 Jan;8(1):115-26. Review.

PMID:
15679179
14.

Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.

Hu S, Yen Y, Ann D, Wong DT.

Drug Discov Today. 2007 Nov;12(21-22):911-6. Review.

PMID:
17993408
15.

Serum chemical biomarkers of cardiac injury for nonclinical safety testing.

Walker DB.

Toxicol Pathol. 2006;34(1):94-104. Review.

PMID:
16507550
16.

Protein biomarkers and drug design for cancer treatments.

Hanke JH, Webster KR, Ronco LV.

Eur J Cancer Prev. 2004 Aug;13(4):297-305. Review.

PMID:
15554558
17.

Proteomic analysis of renal diseases: unraveling the pathophysiology and biomarker discovery.

Thongboonkerd V.

Expert Rev Proteomics. 2005 Jun;2(3):349-66. Review.

PMID:
16000082
18.

Technology Insight: biomarker development in acute kidney injury--what can we anticipate?

Molitoris BA, Melnikov VY, Okusa MD, Himmelfarb J.

Nat Clin Pract Nephrol. 2008 Mar;4(3):154-65. doi: 10.1038/ncpneph0723. Review.

PMID:
18227821
19.

Mechanistic biomarkers for cytotoxic acute kidney injury.

Vaidya VS, Bonventre JV.

Expert Opin Drug Metab Toxicol. 2006 Oct;2(5):697-713. Review.

PMID:
17014390
20.

Cancer biomarkers: current issues and future directions.

Jain KK.

Curr Opin Mol Ther. 2007 Dec;9(6):563-71. Review.

PMID:
18041667
Items per page

Supplemental Content

Support Center